Maribavir

Cytomegalovirus infection after transplantation is a long-standing clinically perplexing immunosuppression-related complication. Existing drugs generally have clinical pain points of high drug resistance and obvious adverse reactions, while the advent of maribavir provides a brand-new treatment option for such patients. As a new-generation oral cytomegalovirus pUL97 kinase inhibitor, it blocks viral replication by targeted inhibition of the activity of viral kinases, avoiding adverse reactions such as myelosuppression and nephrotoxicity caused by traditional nucleoside drugs. It is mainly used to treat post-transplant cytomegalovirus infections that are resistant to conventional treatments such as ganciclovir and valganciclovir, covering immunocompromised adults and children aged 12 years and above who have received hematopoietic stem cell transplantation, solid organ transplantation, etc.

The global market size of maribavir was approximately USD 320 million in 2023, and it is expected to grow to USD 770 million by 2028 at a compound annual growth rate of 18.7%. The current market is still dominated by the original research product, and the layout of generic drugs is still in the early stage. As one of the major organ transplantation countries in the world, China has a stock of more than 200,000 transplant patients and over 20,000 new transplant surgeries per year. The demand for treatment related to cytomegalovirus infection continues to rise, and unmet clinical needs have made this variety a potential track in the anti-infective field.

The original research enterprise of maribavir is Takeda Pharmaceutical, and the original brand name is Livtencity. Its core compound patent in the United States will expire in 2033, and the compound patent in China will expire in 2034. The approved dosage form of the original research product is oral tablet, with specifications including 200mg and 400mg. It has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in the Chinese Catalog of Reference Listed Drugs for Chemical Drugs. No original research preparation has been approved for marketing in mainland China, and no approved maribavir API registration number with A status has been found on the API registration platform for the time being, with only a small number of enterprises in the R&D and declaration stage. (Data as of May 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for maribavir API, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products comply with the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully support the full-process needs of enterprises in API R&D, quality research and registration declaration.